Kekre, NatashaMarquez-Malaver, Francisco JCabrero, MonicaPiñana, JlEsquirol, AlbertSoiffer, Robert JCaballero, DoloresTerol, M JMartino, RodrigoAntin, Joseph HLopez-Corral, LSolano, CarlosArmand, PhilippePérez-Simon, Jose A2023-01-252023-01-252016-07-25http://hdl.handle.net/10668/10311There is at present little data to guide the choice of conditioning for patients with lymphoma undergoing reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT). In this study, we compared the outcomes of patients undergoing RIC SCT who received fludarabine and melphalan (FluMel), the standard RIC regimen used by the Spanish Group of Transplantation, and fludarabine and busulfan (FluBu), the standard RIC regimen used by the Dana-Farber Cancer Institute/Brigham and Women's Hospital. We analyzed 136 patients undergoing RIC SCT for lymphoma with either FluBu (n = 61) or FluMel (n = 75) conditioning between 2007 and 2014. Median follow-up was 36 months. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 13% with FluBu and 36% with FluMel (P = .002). The cumulative incidence of nonrelapse mortality (NRM) at 1 year was 3.3% with FluBu and 31% with FluMel (P enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AllogeneicBusulfanFludarabineLymphomaMelphalanReduced-intensity conditioningStem cell transplantationAdultAntineoplastic Combined Chemotherapy ProtocolsBusulfanFemaleFollow-Up StudiesGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLymphomaMaleMelphalanMiddle AgedSurvival RateTransplantation ConditioningVidarabineresearch article27470290open access10.1016/j.bbmt.2016.07.0061523-6536http://www.bbmt.org/article/S1083879116302221/pdf